학술논문
BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small-cell neuroendocrine carcinoma (SCNC) phenotype-Phase 2a interim results.
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15277755